Today, on May 19, 2017, Emotra AB (publ) held an extraordinary general meeting of shareholders. The resolution, summarised below, was adopted with the necessary majority. 170503 - Emotra - Notice of EGM_EN 170519 - Emotra- PM - EGM bulletin
Today, May 15, 2017, the Board of Directors of Emotra AB (“Emotra”) announced that the Company’s management team has been busy during the weeks since our consensus meeting in Rome and the EPA conference in Florence preparing the market introduction of EDOR®. The Company is planning five training sessions, of which two will take place [...]
Emotra presenterades under ”Aktiedagen”, som arrangeras av Aktiespararna, i Göteborg, idag den 8 maj, kl. 08:30 – 09:00. Nedan återfinns en direktlänk till presentationen. 170508 - Emotra - Nyhetsbrev - Emotras presentation under Aktiedagen i Göteborg
Notice is hereby given that an extraordinary general meeting of shareholders in Emotra AB (publ), 556612-1579, will be held at 12 noon on Friday May 19, 2017 at the restaurant John Scott´s Pub, at 15 Kungsportsavenyn in Göteborg, Sweden. 170503 - Emotra - Notice of EGM_EN
The Board of Directors of Emotra AB (Emotra) is hereby serving notice for an extraordinary shareholder meeting to be held on May 19, 2017. This meeting is being held to vote on a resolution to grant the Board the authority to carry out a new share issue with right of priority for existing shareholders for [...]
The Board and CEO of Emotra AB (publ) hereby present the interim report for the first quarter 2017. 170426- Interim report Jan-Mar 2017_EN
Emotra’s management team has just returned from several days of hard work and successes in connection with the EPA’s conference in Florence, Italy. Researchers from a number of countries have reached out to congratulate us on our successfully concluded study and to register their interest in learning more about EDOR®. Professor Marco Sarchiapone presented our [...]
The Emotra clinical multicentre study, EUDOR-A, which was started during the spring of 2014, has been finalized. The study clearly demonstrates a lower number of suicides in comparison with previous studies, particularly and statistically significantly in the hyporeactive group. During the meeting between participants in the study in Rome the last two days, 29th to [...]
The European Commission, EC, has rejected Emotra’s application, submitted in January 2017, for approximately 3 MEUR, intended for three purposes: First of all to finance EUDOR-Y, a clinical multi-centre study on young people, secondly to develop EDOR® Interconnect, and thirdly to further develop our hardware and software solutions. Similar to last time, the application cleared [...]
The Board and CEO of Emotra AB herewith present the year-end report for the financial year 2016. 170215 - Year-end report 2016